Stocktoria
LIGAND PHARMACEUTICALS INC LGND
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 1992-11-18
LIGAND PHARMACEUTICALS INC statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | 15.3% | -13.5% | 9.1% | 1.5% | 43.0% |
| Net margin | 46.4% | -2.4% | 39.7% | -17.0% | 23.7% |
| FCF margin | 18.2% | 57.0% | 35.1% | 61.1% | 29.0% |
| Return on assets | 8.0% | -0.4% | 6.6% | -4.4% | 4.4% |
| Return on equity | 12.2% | -0.5% | 7.4% | -5.6% | 7.0% |
| Current ratio | 22.23 | 8.93 | 14.15 | 2.67 | 11.15 |
| Revenue growth | 60.4% | 27.3% | -33.1% | -18.8% | 47.7% |
Source: SEC EDGAR filings · CIK 0000886163 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.